Organization
Novartis International AG
Topic
All Topics
People
Find news about people
Alumni
Find news on alumni of any org
Industries
Find news on a particular market
Your Contacts
Find news on your contacts
Sign up for free daily alerts on this feed:
By pressing Sign Up, you agree to our Terms of Use, Privacy Policy, and the LexisNexis Terms & Conditions

Follow

Change Feed
Novartis International AG
... The favorable reimbursement plans will further accelerate growth. Key players include Novartis International AG, Amgen Inc., Merck & Co., Inc., Bristol-Myers Squibb, GlaxoSmithKline Plc, F. ...
... in Africa, with more than 500,000 deaths Basel, 15 November 2017 - Novartis, the American Society for Clinical Pathology (ASCP) and the American Cancer Society ...
... drugs. This report provides revenue forecast for these leading drugs: - Coartem (Novartis) - Clindamycin (Pfizer) - Dengvaxia (Sanofi) - AmBisome (Gilead Sciences) - Impavido ...
... Novartis International AG / Novartis announces study data demonstrating Cosentyx(R) reduced signs and symptoms ...
... - AmBisome (Gilead Sciences) - Dengvaxia (Sanofi) - Clindamycin (Pfizer) - Coartem (Novartis) ยท This report also breaks down the revenue forecast for theGlobal Treatment ...
... Novartis International AG / Novartis and UC Berkeley collaborate to tackle 'undruggable' disease targets ...
... Novartis International AG / Novartis and The Max Foundation transform pioneering cancer access program ...
... Novartis International AG / Novartis drug Rydapt(R) (midostaurin) receives EU approval for newly diagnosed ...
... Novartis International AG / Novartis' Xolair(R) confirms re-treatment efficacy in chronic spontaneous urticaria patients ...
... Novartis International AG / Sandoz proposed biosimilar adalimumab matches reference biologic in terms of ...
... Novartis International AG / Novartis' Cosentyx(R) sets new benchmark in psoriasis with robust 5-year ...
... Novartis International AG / Novartis Phase III study demonstrates adjuvant Tafinlar(R) + Mekinist(R) reduced ...
... Novartis International AG / Novartis presents new data at EURETINA 2017 confirming Lucentis(R) efficacy ...
... Novartis International AG / Novartis presents new analysis demonstrating AMG 334 (erenumab) significantly reduced ...
... Novartis International AG / Novartis landmark Phase III trial shows fingolimod significantly reduces relapses ...
... Novartis International AG / Novartis receives first ever FDA approval for a CAR-T cell ...
... Novartis International AG / Novartis announces analysis published in The Lancet showing ACZ885 reduced ...
... Novartis International AG / Novartis appoints Bertrand Bodson as Chief Digital Officer . Processed ...
... Novartis International AG / Novartis Kisqali(R) (ribociclib) receives EU approval as first-line treatment for ...
Want to see the full history of news or view news on a particular date? Upgrade to RelSci Professional now!
Start My Free Trial ➤